Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Lockridge Grindal Nauen P.L.L.P. Announces Filing of a Securities Class Action Against Alexion Pharmaceuticals, Inc.

GlobeNewswire November 22, 2016

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire November 21, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alexion Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – ALXN

GlobeNewswire November 21, 2016

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire November 21, 2016

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017

GlobeNewswire November 21, 2016

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm

Business Wire November 18, 2016

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Alexion Pharmaceuticals, Inc. (ALXN)

GlobeNewswire November 18, 2016

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire November 18, 2016

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017

PR Newswire November 18, 2016

INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire November 17, 2016

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Alexion Pharmaceuticals, Inc. To Contact The Firm Before Lead Plaintiff Deadline

GlobeNewswire November 17, 2016

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. Limited and Encourages Investors with Losses to Contact the Firm

Business Wire November 17, 2016

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. – ALXN

Business Wire November 17, 2016

New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris® (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant

Business Wire November 17, 2016

Pomerantz Law Firm Announces the Filing of a Class Action against Alexion Pharmaceuticals, Inc. and Certain Officers – ALXN

GlobeNewswire November 17, 2016

Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q

Business Wire November 16, 2016

ALEXION NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Alexion Pharmaceuticals, Inc. To Contact The Firm

PR Newswire November 16, 2016

How These Biotech Stocks are Faring? -- Alexion Pharma, Progenics Pharma, Omeros, and Chimerix

PR Newswire November 16, 2016

EQUITY ALERT: Khang & Khang LLP Announces an Investigation of Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire November 11, 2016

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN

PR Newswire November 11, 2016